Ozempic is a GLP-1 receptor agonist licensed for type 2 diabetes treatment, administered as a once-weekly subcutaneous injection
I need to see large-scale human trials showing safety and efficacy
After an oral glucose load or a meal, this DPP-4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased responsiveness of insulin release to glucose, resulting in higher C-peptide and insulin concentrations
The immune and autonomic nervous systems are highly sensitive to redox imbalances
A United States study found that it had no effect on ACTH, prolactin, follicle stimulating hormone, luteinizing hormone, Thyroid stimulating hormone, or cortisol secretion (1)
It was like I was with Boss